Gilead's new HIV combo measures up to Stribild with better safety; Imprimis takes on Turing with Daraprim competitor;

@FierceBiotech: Gene therapy for brain protein boosts memory in aged mice. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Moderna launches the 3rd or 4th personalized cancer vaccine co. in a month. Release | Follow @JohnCFierce

@DamianFierce: Casting the Coen Bros. $VRX movie: Clooney obviously plays Ackman, and then maybe John Goodman for Pearson. William H. Macy as Pyott? | Follow @DamianFierce

> Gilead Sciences' ($GILD) latest combination treatment for HIV proved itself equal to the company's Stribild in two Phase III trials, all while posting a statistically significantly better safety profile, the company said. The new drug, Genvoya, combines emtricitabine, approved as Emtriva; cobicistat, cleared as Tybost; elvitegravir, on the market as Stribild; and the investigational tenofovir alafenamide, which is a souped-up version of the active ingredient in the company's Viread. Genvoya is up for FDA approval next month. News

> Roche ($RHHBY) CEO Severin Schwan said his company is less exposed to the drug pricing concerns dominating the news in the U.S. because it is "focused exclusively on highly innovative, differentiated medicines." More

> Months after Turing Pharmaceuticals jacked up the price of the toxoplasmosis treatment Daraprim, Imprimis ($IMMY) says it will launch a compounded drug that includes the same active ingredient and sell it at $99 for a 100-count bottle. Story

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Silk Road reels in $57M to commercialize its system for stroke prevention. Article | Follow @VarunSaxena2

@EmilyWFierce: Subway ups the ante on antibiotic-free meat pledge. FierceAnimalHealth story | Follow @EmilyWFierce

> Masimo unveils smart glasses patient monitoring tech. News

> Qualcomm's newly acquired Capsule launches smart patient monitoring system. More

Pharma News

@FiercePharma: Parnell shares advance on strong Q3 revenue growth. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI: After shutting plant over mold issues, France's  decides using CMOs makes more sense. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Good news for Allergan: Men want to treat wrinkles. Bad? They're clueless about products. FiercePharmaMarketing article | Follow @CarlyHFierce

> Perrigo to slash 800 jobs, buy back $2B of its stock in move to fend off Mylan. Story

> Compounder targets Turing's now-pricey Daraprim with $1-per-pill alternative. Article

> Valeant shares nosedive on short seller's 'phantom sales' allegations. Report

CRO News

> Quintiles pairs up with IMS to use real-world data in Phase III trials. Report

> BioClinica revamps its CRO partner program. Item

> SRI inks a $100M contract with NIH to study treatments for radiation exposure. More

> Quintiles shuffles its C-suite with new CFO, COO. News

> Evotec partners up for rare disease R&D in a discovery deal. Article

Pharma Manufacturing News

> Roche partner Chugai significantly expanding antibody capacity at Japan plant. Story

> Biogen's manufacturing feels the pain of its cost-cutting. Report

> Perrigo to consolidate supply chain operations as part of downsizing. Item

> Feds get guilty pleas from suppliers in massive drug diversion operation. More

> AstraZeneca opens plant in Russia. News

Pharma Asia News

> Abbott still eager for emerging markets, but currency headwinds an issue. Article

> Asia's dengue epidemic highlights race for treatment, vaccine options. More

> Chinese hackers said to target U.S. tech and pharma companies. Report

> BeiGene heads to Nasdaq with $100M IPO in China oncology boom. Story

> Yabao expands ties in diabetes pact with a busy Eli Lilly in China. Article

Suggested Articles

Novartis is ending early discovery at its R&D site in Shanghai to “rebalance” its discovery and early development efforts.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year.